Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
1.120
-0.080 (-6.67%)
Oct 14, 2026, 4:00 PM EDT - Market closed
Radiopharm Theranostics Employees
Radiopharm Theranostics had 14 employees as of June 30, 2026. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$635,723
Profits / Employee
-$2,814,177
Market Cap
15.10M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 14 | 0 | - |
| Jun 30, 2025 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Palatin Technologies | 25 |
| Daré Bioscience | 24 |
| Jasper Therapeutics | 22 |
| BioCardia | 21 |
| Kiora Pharmaceuticals | 13 |
| NewcelX | 12 |
| Psyence Biomedical | 12 |
RADX News
- 9 days ago - Radiopharm completes EOP2 meeting with FDA for RAD101 - TheFly
- 15 days ago - Radiopharm Theranostics Annual report: H2 2026 - Filings
- 4 weeks ago - Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up - Nasdaq
- 4 weeks ago - Radiopharm Theranostics Registration statement: Registration filing - Filings
- 5 weeks ago - Radiopharm announces data from imaging trial of RAD 301 - TheFly
- 5 weeks ago - Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 7 weeks ago - Radiopharm doses first patient in second cohort of RV-01 trial - TheFly
- 7 weeks ago - Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - GlobeNewsWire